Public articles linked to the same research event.
Therapeutic delivery This review searched PubMed, Scopus, Web of Science, and Google Scholar for literature up to March 2026 and synthesized the preclinical evidence, safety and regulatory considerations, and clinical development path for intranasal cannabidiol (CBD) delivered via nanostructured lipid carriers (NLCs) in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), noting that intranasal NLC-CBD increased brain CBD levels, enhanced brain targeting, and prolonged central exposure in animal models, while properly designed clinical trials are still needed to establish safety, pharmacokinetics, and efficacy in pediatric DS and LGS patients.
This review searched PubMed, Scopus, Web of Science, and Google Scholar for literature up to March 2026 and synthesized the preclinical evidence, safety and regulatory considerations, and clinical development path for intranasal cannabidiol (CBD) delivered via nanostructured lipid carriers (NLCs) in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), noting that intranasal NLC-CBD increased brain CBD levels, enhanced brain targeting, and prolonged central exposure in animal models, while properly designed clinical trials are still needed to establish safety, pharmacokinetics, and efficacy in pediatric DS and LGS patients.
This review searched PubMed, Scopus, Web of Science, and Google Scholar for literature up to March 2026 and synthesized the preclinical evidence, safety and regulatory considerations, and clinical development path for intranasal cannabidiol (CBD) delivered via nanostructured lipid carriers (NLCs) in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), noting that intranasal NLC-CBD increased brain CBD levels, enhanced brain targeting, and prolonged central exposure in animal models, while properly designed clinical trials are still needed to establish safety, pharmacokinetics, and efficacy in pediatric DS and LGS patients.
This review searched PubMed, Scopus, Web of Science, and Google Scholar for literature up to March 2026 and synthesized the preclinical evidence, safety and regulatory considerations, and clinical development path for intranasal cannabidiol (CBD) delivered via nanostructured lipid carriers (NLCs) in Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), noting that intranasal NLC-CBD increased brain CBD levels, enhanced brain targeting, and prolonged central exposure in animal models, while properly designed clinical trials are still needed to establish safety, pharmacokinetics, and efficacy in pediatric DS and LGS patients.